FI67845C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara xylitolderivat - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara xylitolderivat Download PDFInfo
- Publication number
- FI67845C FI67845C FI791484A FI791484A FI67845C FI 67845 C FI67845 C FI 67845C FI 791484 A FI791484 A FI 791484A FI 791484 A FI791484 A FI 791484A FI 67845 C FI67845 C FI 67845C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- halogen
- defined above
- xylitol
- phenyl
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 31
- 239000002253 acid Substances 0.000 claims description 14
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 239000000811 xylitol Substances 0.000 claims description 9
- 229960002675 xylitol Drugs 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000002516 radical scavenger Substances 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 241000251730 Chondrichthyes Species 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 229910000039 hydrogen halide Inorganic materials 0.000 claims description 2
- 239000012433 hydrogen halide Substances 0.000 claims description 2
- 125000005270 trialkylamine group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- -1 sugar alcohol compounds Chemical class 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000010447 xylitol Nutrition 0.000 description 6
- 230000001085 cytostatic effect Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- FZQZRBQKXXGAMZ-UHFFFAOYSA-N 2-benzyl-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1CC1=CC=CC=C1 FZQZRBQKXXGAMZ-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- YGJKHTNKXAUYCR-SCDXWVJYSA-N BrC[C@H](O)[C@@H](O)[C@H](O)CBr Chemical compound BrC[C@H](O)[C@@H](O)[C@H](O)CBr YGJKHTNKXAUYCR-SCDXWVJYSA-N 0.000 description 2
- GSWQIGIUMPTMRX-VQFNDLOPSA-N C1(=CC=CC=C1)C1=CC=C(C(=O)[C@]([C@H](CBr)O)(O)[C@H](O)CBr)C=C1 Chemical compound C1(=CC=CC=C1)C1=CC=C(C(=O)[C@]([C@H](CBr)O)(O)[C@H](O)CBr)C=C1 GSWQIGIUMPTMRX-VQFNDLOPSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061968 Gastric neoplasm Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 2
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- DHKVCYCWBUNNQH-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)C=NN2 DHKVCYCWBUNNQH-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- JPVUWCPKMYXOKW-UHFFFAOYSA-N 4-phenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CC=CC=C1 JPVUWCPKMYXOKW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZILGFHCSKFFZAT-SCDXWVJYSA-N ClC[C@H](O)[C@@H](O)[C@H](O)CCl Chemical compound ClC[C@H](O)[C@@H](O)[C@H](O)CCl ZILGFHCSKFFZAT-SCDXWVJYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical class OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- QYEVBJRIMBKJCW-SCDXWVJYSA-N IC[C@H](O)[C@@H](O)[C@H](O)CI Chemical compound IC[C@H](O)[C@@H](O)[C@H](O)CI QYEVBJRIMBKJCW-SCDXWVJYSA-N 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000011021 lapis lazuli Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/62—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/64—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by simultaneous introduction of -OH groups and halogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C31/34—Halogenated alcohols
- C07C31/42—Polyhydroxylic acyclic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUCI001826 | 1978-05-11 | ||
| HU78CI1826A HU176216B (en) | 1978-05-11 | 1978-05-11 | Process for producing terminally bifuntional xylite derivatives of citostatic activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI791484A7 FI791484A7 (fi) | 1979-11-12 |
| FI67845B FI67845B (fi) | 1985-02-28 |
| FI67845C true FI67845C (fi) | 1985-06-10 |
Family
ID=10994695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI791484A FI67845C (fi) | 1978-05-11 | 1979-05-09 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara xylitolderivat |
Country Status (26)
| Country | Link |
|---|---|
| JP (1) | JPS5522662A (cs) |
| AR (1) | AR222332A1 (cs) |
| AT (1) | AT361945B (cs) |
| BE (1) | BE876166A (cs) |
| CA (1) | CA1145349A (cs) |
| CH (1) | CH641437A5 (cs) |
| CS (1) | CS211399B2 (cs) |
| DD (1) | DD143765A5 (cs) |
| DE (1) | DE2917538A1 (cs) |
| DK (1) | DK195279A (cs) |
| EG (1) | EG15150A (cs) |
| ES (1) | ES480869A1 (cs) |
| FI (1) | FI67845C (cs) |
| FR (1) | FR2425445A1 (cs) |
| GB (1) | GB2024204B (cs) |
| GR (1) | GR68495B (cs) |
| HU (1) | HU176216B (cs) |
| IL (1) | IL57182A (cs) |
| IN (1) | IN150040B (cs) |
| IT (1) | IT1118485B (cs) |
| NL (1) | NL7903634A (cs) |
| NO (1) | NO153928C (cs) |
| PL (1) | PL121560B1 (cs) |
| SE (1) | SE7904080L (cs) |
| SU (1) | SU984410A3 (cs) |
| YU (1) | YU108079A (cs) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH381666A (de) * | 1958-04-24 | 1964-09-15 | Nat Res Dev | Verfahren zur Herstellung von Derivaten von polyhydrischen Alkoholen |
| DE1668241A1 (de) * | 1968-03-06 | 1971-02-11 | Herbrand Kg Dr | Therapeutisch wirksame 1,5-di-substituierte Derivate von Xylit,Adonit und Arabit |
-
1978
- 1978-05-11 HU HU78CI1826A patent/HU176216B/hu unknown
-
1979
- 1979-04-30 IL IL57182A patent/IL57182A/xx unknown
- 1979-04-30 DE DE19792917538 patent/DE2917538A1/de not_active Withdrawn
- 1979-05-02 IN IN447/CAL/79A patent/IN150040B/en unknown
- 1979-05-06 EG EG264/79A patent/EG15150A/xx active
- 1979-05-07 GR GR59037A patent/GR68495B/el unknown
- 1979-05-09 FI FI791484A patent/FI67845C/fi not_active IP Right Cessation
- 1979-05-09 YU YU01080/79A patent/YU108079A/xx unknown
- 1979-05-09 FR FR7911733A patent/FR2425445A1/fr active Granted
- 1979-05-09 NL NL7903634A patent/NL7903634A/xx not_active Application Discontinuation
- 1979-05-09 SE SE7904080A patent/SE7904080L/xx not_active Application Discontinuation
- 1979-05-10 IT IT67984/79A patent/IT1118485B/it active
- 1979-05-10 GB GB7916274A patent/GB2024204B/en not_active Expired
- 1979-05-10 AR AR276464A patent/AR222332A1/es active
- 1979-05-10 DK DK195279A patent/DK195279A/da not_active Application Discontinuation
- 1979-05-10 AT AT347779A patent/AT361945B/de not_active IP Right Cessation
- 1979-05-10 JP JP5758879A patent/JPS5522662A/ja active Pending
- 1979-05-10 CH CH438979A patent/CH641437A5/de not_active IP Right Cessation
- 1979-05-10 BE BE0/195089A patent/BE876166A/xx not_active IP Right Cessation
- 1979-05-10 PL PL1979215489A patent/PL121560B1/pl unknown
- 1979-05-10 NO NO791564A patent/NO153928C/no unknown
- 1979-05-10 CS CS793205A patent/CS211399B2/cs unknown
- 1979-05-10 CA CA000327317A patent/CA1145349A/en not_active Expired
- 1979-05-11 DD DD79212780A patent/DD143765A5/de unknown
- 1979-05-11 SU SU792764801A patent/SU984410A3/ru active
- 1979-05-11 ES ES480869A patent/ES480869A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| YU108079A (en) | 1982-10-31 |
| GB2024204B (en) | 1982-10-27 |
| DK195279A (da) | 1979-11-12 |
| DE2917538A1 (de) | 1979-11-15 |
| AT361945B (de) | 1981-04-10 |
| IL57182A0 (en) | 1979-07-25 |
| CA1145349A (en) | 1983-04-26 |
| BE876166A (fr) | 1979-09-03 |
| FI791484A7 (fi) | 1979-11-12 |
| SU984410A3 (ru) | 1982-12-23 |
| IL57182A (en) | 1983-07-31 |
| GR68495B (cs) | 1982-01-07 |
| ES480869A1 (es) | 1980-06-16 |
| PL215489A1 (cs) | 1980-02-11 |
| FI67845B (fi) | 1985-02-28 |
| DD143765A5 (de) | 1980-09-10 |
| NO153928B (no) | 1986-03-10 |
| IN150040B (cs) | 1982-07-03 |
| NL7903634A (nl) | 1979-11-13 |
| NO791564L (no) | 1979-11-13 |
| AR222332A1 (es) | 1981-05-15 |
| IT7967984A0 (it) | 1979-05-10 |
| HU176216B (en) | 1981-01-28 |
| NO153928C (no) | 1986-06-18 |
| ATA347779A (de) | 1980-09-15 |
| CH641437A5 (de) | 1984-02-29 |
| IT1118485B (it) | 1986-03-03 |
| EG15150A (en) | 1985-12-31 |
| FR2425445B1 (cs) | 1984-06-08 |
| PL121560B1 (en) | 1982-05-31 |
| GB2024204A (en) | 1980-01-09 |
| JPS5522662A (en) | 1980-02-18 |
| FR2425445A1 (fr) | 1979-12-07 |
| SE7904080L (sv) | 1979-11-12 |
| CS211399B2 (en) | 1982-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4658058A (en) | 11-O-methylspergualin | |
| US6124293A (en) | Semi-synthetic ecteinascidins | |
| US5103018A (en) | Mitomycin derivatives | |
| EP0323171A2 (en) | Novel K-252 derivatives having anti-tumor activity and pharmaceutical compositions containing them | |
| NO175620B (cs) | ||
| DK146626B (da) | Analogifremgangsmaade til fremstilling af 4'-deoxydaunomycin | |
| US4268676A (en) | Mitomycin analogs | |
| EP0468400A1 (en) | DC-89 derivatives as antitumoral agents | |
| US5441932A (en) | Sugar compounds for inhibition of the biosynthesis of sugar chains containing sialic acid | |
| FI61693C (fi) | Analogifoerfarande foer framstaellning av farmaceutiskt aktivaindolderivat | |
| FI62316C (fi) | Foerfarande foer framstaellning av di- eller trisubstituerade estrar av daunorubicinderivat vilka aer anvaendbara vid behandling av tumoerer | |
| FI67845C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara xylitolderivat | |
| EP0157623B1 (en) | Optically active isomers of benzopyran derivatives useful for treating cardiovascular disease | |
| US4275192A (en) | Bis(4-demethoxydaunorubicin)dihydrazone derivatives and pharmacologically acceptable salts thereof | |
| US3957795A (en) | Novel cyclopentene and cyclopentane derivatives | |
| JPS6260393B2 (cs) | ||
| FI66607B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,2-5,6-dianhydro-hexitoler | |
| FI71934B (fi) | Foerfarande foer framstaellning av nya n-substituerade polyglycidyl-urazolfoereningar | |
| JPH06211762A (ja) | Ｎ−メチルデアセチルコルヒセインアミド誘導体 | |
| PL101458B1 (pl) | Sposob wytwarzania nowych pochodnych dwuanhydroheksytolu | |
| EP0104631A2 (en) | Clavulone derivatives, process for preparing the same, and use of said compounds | |
| EP0191375A2 (en) | 7-n-aminomethylenemitomycin derivatives, process for production thereof and anti-tumor composition | |
| US4576945A (en) | Hexaalkylmelamine-amino-oxy compounds | |
| FI85140C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-(1h-indol-4-yl)-bensamidderivat. | |
| US3996284A (en) | Naphthyl and tetrahydronaphthyl di-ethers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: CHINOIN GYOGUSZER ES VEGYESZETI TERMEKEK |